Vapotherm raises $20.5 million in equity financing

The financing was led by GE Asset Management (on behalf of the General Electric Pension Trust), with participation by Cross Creek Capital (a Wasatch Advisors company) and Integral Capital Partners – all three are new investors in Vapotherm. Existing investors of Vapotherm, QuestMark Partners and Kaiser Permanente Ventures, also participated in the round.

The financing is expected to support the company’s growth plans including new product development, sales expansion and the launch of Vapotherm’s newest acute care device, Precision Flow, which recently earned 510(k) clearance from the FDA.

Brian Stansky, managing director of Integral Capital Partners, said: “We are excited about the broad application potential for Vapotherm’s high flow therapy system to create multiple franchises in the treatment of respiratory conditions, sleep apnea, and drug delivery.”